Novo Nordisk A/S (NVO) P/FCF 40.7 | Overview

Search global stocks & ETFs...Ctrl K

Learn Mode

Novo Nordisk A/SNVO

$42.96

-$0.79 (-1.806%)

at close

$42.75

-$0.21 (-0.499%)

after hours · 11:52 PM

4.07/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

Updates

NVO

Stock Profile

Showing data forNOVO B.CO

Market Cap

DKK 1.26T

Industry

Pharmaceuticals

EPS (TTM)

DKK 27.41

P/E (TTM)

10.34

Div & Yield

DKK 11.70 (4.14%)

FCF Payout Ratio

168.23%

P/S (TTM)

3.85

P/B

6.21

Revenue Growth (TTM)

8.13%

EPS CAGR (3Y)

26.50%

Diluted Shares

4.43B

Ex-Dividend

2026-03-27

Next Earnings

08-05

Forward P/E

12.88

Payout Ratio

42.80%

P/FCF (TTM)

40.65

FCF Yield

2.46%

Earnings Yield

9.67%

Revenue CAGR (3Y)

20.29%

Recommended Metric

Score Card

Showing data forNOVO B.CO

Explore Scores Tab

4.07

Good

Novo Nordisk A/S has grown revenue at 8.13% over the past year, which suggests sales are increasing. Also, it has seen its net income increase by 16.58% over the past year, which suggests its profits are growing at a strong rate.

Valuation Model

Key Score

5.00

Very Good

Management

5.00

Very Good

Growth

5.00

Very Good

Profitability

5.00

Very Good

Fin. Health

4.00

Good

Dividends

5.00

Very Good

Analyst

1.00

Very Bad

Financials

Explore Financial Tab ›

Revenue

Earnings

Free Cash Flow

Insider Transactions

Explore Insider Tab ›

Insufficient Insider data to display this section

Peers

Select stocks to compare

ALK B.COAlk-Abello A/s

DKK 266.18

+1.71%

PEG.COPharma Equity Group A/s

DKK 0.07

-6.32%

NOVO B.CONovo Nordisk A/s

DKK 282.74

+3.42%

HLUN A.COH Lundbeck A/s

DKK 37.14

+0.53%

STENO.COStenocare A/s

DKK 1.06

-0.47%

Price Targets & Ratings

View Analysis

1-year price targets, ending May 13, 2027

Current

$42.96

Baseline

High

$73.90

▲

72.02%

Avg

$51.41

▲

19.67%

Low

$28.02

▼

-34.78%

Analyst Ratings based on 37 Analysts

Strong Buy

14%

Buy

19%

Hold

62%

Sell

03%

Strong Sell

03%

About

Website

Address

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.Read More

IPO Date

1974-05-17

Industry

Pharmaceuticals

Total Employees

68,794

Exchange

Omx Nordic Exchange Copenhagen A/S

Reporting Currency

DKK

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

Stock News

View All Updates

Amgen: Time For An Upgrade? Yes, I Think So

SeekingAlpha

4 Health Care Stocks With Whale Alerts In Today's Session

Benzinga

SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For June 2026

SeekingAlpha

Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

Benzinga

Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027

SeekingAlpha

Wall Street Breakfast Podcast: Bitcoin's Great Withdrawal

SeekingAlpha

Madrigal Pharmaceuticals Could Become The Next Vertex

SeekingAlpha

Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)

SeekingAlpha

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class

SeekingAlpha

Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win

SeekingAlpha

Wall Street Underestimates Novo Nordisk's GLP-1 Comeback

SeekingAlpha

CVS Expands GLP-1 Options For Members, Including The Reintroduction Of Zepbound As A Covered Medication

Benzinga

Novo Nordisk Gets European Commission Extension To Marketing Authorisation For Wegovy In EU To Add An Oral Formulation For Weight Management

Benzinga

These Are The Upcoming Catalysts For Crispr Therapeutics Stock

SeekingAlpha

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

SeekingAlpha

Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant

SeekingAlpha

Eli Lilly: Novo Nordisk Was Just A Warm-Up

SeekingAlpha

Novo Nordisk To Unveil Data Showing Semaglutide Tackles The Liver Disease Crisis Affecting About 1 In 3 People Living With Overweight And Obesity Worldwide

Benzinga

Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law

Benzinga

US Supreme Court rebuffs pharma challenge to Biden-era drug price

Finnhub

'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News

Benzinga

Novo Nordisk A/S - share repurchase programme

Finnhub

Why Pfizer Stock Still Looks Deeply Undervalued In 2026

SeekingAlpha

Novo Nordisk slides on signs of slowing sales momentum for Wegovy pill

Finnhub

Hims & Hers Health: The Stock Is On Sale, Buy It

SeekingAlpha

AI In Health Care Is Scaling Quickly—As Regulation Lags, Internal Controls Need To Keep Pace

Finnhub

Novo Nordisk: The First Fruits Of Labor

SeekingAlpha

Hims & Hers Health Is Likely Dead Money

SeekingAlpha

Novo Nordisk: Why I Won't Upgrade

SeekingAlpha

Trump's Drug Pricing Plan Gains Surprise Democratic Ally— Peter Welch Vows To 'Make It Happen'

Benzinga

Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today

Benzinga

Novo Nordisk Highlights New Wegovy Pill Data

Benzinga

Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss

Benzinga

April CPI Inflation: Brace For Margin Pressure

SeekingAlpha

Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic and Wegovy

Finnhub

Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain

SeekingAlpha

Novo Nordisk halts Odense construction and issues layoff notices

Finnhub

Novo Nordisk Says Trial of Wegovy Pill Shows Some Patients Achieve Nearly 22% Weight Loss

Finnhub

Novo Nordisk says Wegovy pill delivers 21.6% weight loss in early responders

Finnhub

NOVO NORDISK : Jefferies reaffirms its Neutral rating

Finnhub

Novo Nordisk: Oral Wegovy yields over 21 percent weight loss in clinical trial

Finnhub

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Finnhub

GLP-1: Winners and Losers in Shifting Consumer Habits

Finnhub

Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction

Benzinga

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Benzinga

Novo Nordisk A/S Demonstrates Higher Dose Wegovy Achieves Nearly 28% Weight Loss in Early Responders

Finnhub

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Finnhub

Novo Nordisk says Wegovy shows average 22.6% weight loss for premenopausal women with obesity

Finnhub

Novo Nordisk Says Wegovy Showed An Average 22.6% Weight Loss For Premenopausal Women With Obesity, With More Than 41% Achieving 25% Or More Weight Loss

Benzinga

Scroll for more · 50 articles